【美股财报】Taysha Gene Therapies Inc 2024年度报告.pdf

Intra-Cellular Therapies Inc 2024年度报告

Taysha Gene Therapies Inc美股招股说明书(2025-05-28版)

Considerations for the use of anthelminthic therapy for the treatment of neurocysticercosis

Access to oncology combination therapies in Europe moving forward

Medical Rationale Supporting Patient Access To Novel Oncology Combination Therapies

BioRestorative Therapies Inc 2024年度报告

AK112 to validate its potential as next-generation IO therapy

OS Therapies Inc 2025年季度报告